Format

Send to

Choose Destination
Eur J Cancer. 2014 Oct;50(15):2532-43. doi: 10.1016/j.ejca.2014.07.013. Epub 2014 Aug 4.

On the use of pharmacogenetics in cancer treatment and clinical trials.

Author information

1
INSERM U916, Institut BergoniƩ, University of Bordeaux, France. Electronic address: j.robert@bordeaux.unicancer.fr.
2
INSERM U916, Institut BergoniƩ, University of Bordeaux, France.
3
Department of Medical Oncology, VU University Medical Centre, Amsterdam, The Netherlands.

Abstract

There are an increasing number of studies devoted to the identification of associations between anticancer drug efficacy and toxicity and common polymorphisms present in the patients' genome. However, many articles presenting the results of such studies do not bring the simple and necessary background information allowing the evaluation of the relevance of the study, its significance and its potential importance for patients' treatment. This position paper first addresses clinical oncologists with the aim of giving them the basic knowledge on pharmacogenetics and on the potential use of gene polymorphisms as predictive biomarkers in routine and clinical research. A secondary objective is to give molecular biologists some recommendations on how to conceive protocols and how to publish their results when they develop pharmacogenetic studies appended to clinical trials or with autonomous goals.

KEYWORDS:

Anticancer drug response; Anticancer drug toxicity; Biomarkers; Cancer clinical trials; Cancer treatments; Gene polymorphisms; Pharmacogenetics

PMID:
25103456
DOI:
10.1016/j.ejca.2014.07.013
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center